The conference call is scheduled for Monday, April 15th at 8:00 a.m. ET
The registration link below has been updated
NOVATO, Calif., April 12, 2024 (Globe Newswire) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced new clinical efficacy and safety data from a Phase 1/2 study of GTX-102. We announced that we have held a conference call to discuss. Treatments for Angelman Syndrome to be presented at the American Academy of Neurology Meeting (AAN) will be held on Monday, April 15, 2024 at 8 a.m. Eastern Time (ET). Slides accompanying the conference call will be shared on the company's website (https://ir.ultragenyx.com/events-presentations) prior to the conference call.
Conference call and webcast information
A live and replayed webcast of the call will be available on the company's website at https://ir.ultragenyx.com/events-presentations.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing new products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company aims to address diseases with high unmet medical need and distinct biology for treatment, where there is typically no approved therapy to treat the underlying disease. We have built a diverse portfolio of approved treatments and product candidates.
The company is led by a management team with experience in the development and commercialization of rare disease drugs. Ultragenyx's strategy is premised on time- and cost-effective drug development, with the goal of bringing safe and effective treatments to patients with the utmost urgency.
For more information about Ultragenyx, please visit the company's website at www.ultragenyx.com.
contact address
Ultragenics Pharmaceutical Co., Ltd.
Investor
Higa Joshua
+1-415-475-6370
ir@ultragenyx.com
media
carolyn wang
+1-415-225-5050
media@ultragenyx.com